{"slideshow_credits": null, "snippet": "Vigilant oversight is needed to prevent drug companies from buying off competitors or forcing switches to newer drugs.", "abstract": "Editorial applauds Federal Trade Commission and state officials like New York Atty Gen Eric Schneiderman for vigilant oversight of drug manufacturers using underhanded tactics; notes manufacturers of brand-name drugs were trying to ward off competition from less expensive generic drugs in order to continue high levels of profit on pharmaceuticals; holds consumers and insurers deserve full access to safe, effective and far less costly generic equivalents.", "section_name": "Opinion", "print_page": "20", "document_type": "article", "byline": {"person": [], "original": "By THE EDITORIAL BOARD", "organization": "THE EDITORIAL BOARD"}, "web_url": "http://www.nytimes.com/2015/06/08/opinion/sneaky-ways-to-raise-drug-profits.html", "lead_paragraph": "Vigilant oversight is needed to prevent drug companies from buying off competitors or forcing switches to newer drugs.", "headline": {"print_headline": "Sneaky Ways to Raise Drug Profits", "main": "Sneaky Ways to Raise Drug Profits", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "5575427338f0d8502adcc2c5", "word_count": "485", "multimedia": [{"height": 126, "url": "images/2015/06/06/opinion/08mon2web/08mon2web-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/06/06/opinion/08mon2web/08mon2web-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/06/06/opinion/08mon2web/08mon2web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/06/06/opinion/08mon2web/08mon2web-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/06/06/opinion/08mon2web/08mon2web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/06/06/opinion/08mon2web/08mon2web-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-06-08T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"name": "subject", "value": "Editorials", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Generic Brands and Products", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Federal Trade Commission", "is_major": "Y", "rank": "3"}, {"name": "persons", "value": "Schneiderman, Eric T", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Attorneys General", "is_major": "Y", "rank": "5"}, {"name": "organizations", "value": "Cephalon Inc", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Actavis PLC", "is_major": "N", "rank": "7"}, {"name": "organizations", "value": "Teva Pharmaceutical Industries Ltd", "is_major": "N", "rank": "8"}, {"name": "subject", "value": "Regulation and Deregulation of Industry", "is_major": "N", "rank": "9"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "10"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}